We've upgraded AI Search on TaxTMI with two powerful modes:
1. Basic • Quick overview summary answering your query with references• Category-wise results to explore all relevant documents on TaxTMI
2. Advanced • Includes everything in Basic • Detailed report covering: - Overview Summary - Governing Provisions [Acts, Notifications, Circulars] - Relevant Case Laws - Tariff / Classification / HSN - Expert views from TaxTMI - Practical Guidance with immediate steps and dispute strategy
• Also highlights how each document is relevant to your query, helping you quickly understand key insights without reading the full text.Help Us Improve - by giving the rating with each AI Result:
Tribunal excludes royalty payment from assessable value, dismisses duty demand on control samples The Tribunal held that the royalty amount paid by the appellant to Abbott, USA, was not includible in the assessable value as no actual payment was made. ...
Cases where this provision is explicitly mentioned in the judgment/order text; may not be exhaustive. To view the complete list of cases mentioning this section, Click here.
Provisions expressly mentioned in the judgment/order text.
Tribunal excludes royalty payment from assessable value, dismisses duty demand on control samples
The Tribunal held that the royalty amount paid by the appellant to Abbott, USA, was not includible in the assessable value as no actual payment was made. Additionally, the duty demand on control samples was dismissed, following precedent that such samples are exempt from excise duty. The impugned order was set aside entirely, with penalties deemed unsustainable. As a result, the appeals were allowed, and the orders overturned on 13.01.2017.
Issues: 1. Whether royalty as per the agreement between the buyer and Abbott, USA is includible in the assessable value of the appellantRs. 2. Whether the control sample is liable to excise dutyRs.
Analysis:
Issue 1: The appellant, engaged in manufacturing SELSUN, had a Registered User Agreement with Abbott Laboratories, USA, where M/s Pharmacia Healthcare Ltd. was to pay a royalty of 2% of gross sales to Abbott, USA. The department alleged that the transaction value was suppressed by the royalty amount. The appellant argued that no royalty was actually paid, and they were not part of the royalty agreement between Pharmacia and Abbott, USA. The Tribunal held that since no payment was made, the royalty amount cannot be included in the assessable value. Referring to Rule 6 of the Central Excise Valuation Rules, the Tribunal ruled in favor of the appellant, setting aside the duty demand related to royalty.
Issue 2: Regarding the duty demand on control samples, the appellant contended that these samples, required by law for post-expiry investigations, were not subject to excise duty. Citing a precedent (Commissioner of Central Excise, Chandigarh Vs. Dabur India Ltd.), the appellant argued that control samples are exempt from duty. The Tribunal agreed, stating that control samples preserved for market or patient complaints are not liable for excise duty. Consequently, the duty demand on control samples was dismissed.
In conclusion, the Tribunal found the impugned order unsustainable and set it aside entirely. Since the demands were not justified, the penalties imposed were also deemed unsustainable. Therefore, the appeals were allowed, and the impugned orders were overturned on 13.01.2017.
Full Summary is available for active users!
Note: It is a system-generated summary and is for quick reference only.